Biotech Values

[DewDiligence]

TLSA—(not TSLA!)+165%—climbs on the COVID-19 bandwagon:

https://www.prnewswire.com/news-releases/tiziana-life-sciences-developing-tzls-501-as-a-potential-treatment-for-coronavirus-patients-301021437.html

Tiziana Life Sciences plc…has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure.

…Tiziana plans to administer TZLS-501 using a proprietary formulation technology. Tests have already shown that the treatment rapidly depletes circulating levels of IL-6 in the blood. An excessive production of IL-6 is regarded as a key driver of chronic inflammation and is believed to be associated with severe lung damage observed with COVID-19 infections and acute respiratory illness.

SNY/REGN are also pursuing the (somewhat counter-intuitive) inhibition of IL-6 as a means of treating COVID-19.